Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP167 in Healthy Volunteers and Mild Dyslipidemia
NCT07412080Phase 1Completed
- Sponsor
- Eddingpharm
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EDP167 in dyslipidemia, sponsored by Eddingpharm. Primary endpoint: Safety and tolerability of a single subcutaneous injection of EDP167 at 85 days. Started Jul 2025; status: completed.
02
Drugs
EDP167
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT07412080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412080.